Author: [email protected]

Release – Snail Games Launches ARK: Genesis Part 1 Ascended, ARK Tides of Fortune, and ARK: Dragontopia DLC; $11 Million from Deferred Revenue Backlog to be Recognized in Q3 2026

Posted on by [email protected]
Snail, Inc logo

Research News and Market Data on SNAL

July 7, 2026 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced the official launch of ARK: Genesis Part 1 Ascended, ARK Tides of Fortune, and ARK: Dragontopia for ARK: Survival Ascended. In connection with the release of ARK: Genesis Part 1 Ascended, the Company expects to recognize approximately $11 million from its deferred revenue backlog in Q3 2026.

The launch of ARK: Genesis Part 1 Ascended marks the return of one of the franchise’s most ambitious DLCs and its iconic ocean biome to the Unreal Engine 5-powered survival experience. Available at no additional cost to ARK: Survival Ascended owners, Genesis Part 1 Ascended expands the game’s content offering with new environments, creatures, and survival challenges.

Launching alongside Genesis Part 1 Ascended is Tides of Fortune, a new premium expansion that transforms the simulated ocean of Genesis into a massive, map-wide nautical frontier. Within this new expansion, players can build fleets, engage in naval warfare, and explore the deepest reaches of ARK‘s oceanic ecosystem.

Additionally, Studio Wildcard shadow-dropped ARK: Dragontopia, an all-new premium expansion pass that introduces survivors to a vast aerial ecosystem where dragons rule the skies. Owners will receive included content updates on July 9 and in October, culminating in December with the release of a boundless skyworld map.

The launch of this trio of content (Genesis Ascended Part 1, Tides of Fortune, and Dragontopia) underscores Snail Games’ strategy of leveraging its established content portfolio to drive player engagement and expand the ARK ecosystem. As the Company continues to invest in franchise development, ARK remains a key pillar of Snail Games’ growth and portfolio.

For creators interested in collaborations, please contact [email protected].

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding recognizing approximately $11 million from the Company’s deferred revenue backlog in Q3 2026 in connection with the release of ARK: Genesis Part 1 Ascended; the sustainable value of prior ARK content and the franchise’s strong long-term player ecosystem; Snail Games’ strategy of leveraging its established content portfolio to drive player engagement and expand the ARK ecosystem; ARK remaining a key pillar of Snail Games’ growth and portfolio as the Company continues to invest in franchise development; and assumptions underlying any of the foregoing. Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business include Snail Games’ ability to strengthen its gaming portfolio’s visibility; Snail Games’ ability to expand and grow its franchise and increase its revenue; Snail Games’ ability to retain its key employees or maintain its Nasdaq listing; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail Games, and Snail Games does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

Release – The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity

Posted on by [email protected]
TOI Management LLC. Logo

Research News and Market Data on TOI

Jul 07, 2026

PDF Version

CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.

This transaction is intended to increase liquidity, improve operating flexibility and extend debt maturities. Under the new financing arrangements with OrbiMed, TOI repaid the outstanding balance of its $86 million senior secured convertible note with a new $75 million term loan with OrbiMed maturing in 2031 as well as approximately $11 million of cash from the balance sheet without raising additional equity. Daniel Virnich, MD, CEO of TOI, commented, “I’m extremely excited about our new financing relationship with OrbiMed to support this next phase of TOI’s growth and business model refinement. In addition to providing the company with improved liquidity and financial flexibility, this important transaction significantly extends debt maturities and establishes committed funding from two leading healthcare financing institutions.” Dr Virnich also commented, “We are very pleased that we were able to complete these transactions without diluting our important existing shareholders, and would like to thank Deerfield Healthcare for their many years of support to TOI as both a creditor and existing shareholder.”

“We are pleased to support TOI in its next phase of growth,” said Matthew Rizzo of OrbiMed. ” We are excited to play a role in TOI’s expansion and development as it continues to scale and drive long term value for its patients and contracted payors.”

About The Oncology Institute  (www.theoncologyinstitute.com):

Founded in 2007, The Oncology Institute, Inc. (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 2.0 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Forward Looking Statement

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or TOI’s future financial or operating performance and are often identified by words such as “believe,” “expect,” “anticipate,” “plan,” “intend,” “may,” “will,” “estimate,” “continue,” “project,” “target,” or similar expressions.

These forward-looking statements include, without limitation, statements regarding TOI’s growth strategy, liquidity, working capital needs, access to financing (including any asset-based credit facilities), expected operational and financial performance, and market opportunities. These statements are based on current expectations, assumptions, and information available to management and are not guarantees of future performance.

Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of risks and uncertainties, including, among others: changes in the healthcare regulatory environment; reimbursement and payor dynamics; competitive pressures; TOI’s ability to execute on its growth and value-based care strategy; access to capital and liquidity; and the impact of litigation, government investigations, or other proceedings.

Additional factors that could cause actual results to differ materially are described in TOI’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of TOI’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Forward-looking statements speak only as of the date made, and TOI undertakes no obligation to update or revise these statements to reflect events or circumstances occurring after the date of this communication, except as required by law.

Media
The Oncology Institute, Inc.
[email protected]

Investors
ICR Healthcare
[email protected]

Release – MariMed’s Nature’s Heritage Launches “The Nose Knows” Immersive, Science-Backed Consumer Education Campaign

Posted on by [email protected]
Primary Logo

Research News and Market Data on MRMD

July 07, 2026 7:00am EDTDownload as PDF

NORWOOD, Mass., July 07, 2026 (GLOBE NEWSWIRE) — MariMed’s (“MariMed”) (CSE: MRMD) (OTCQB: MRMD) award-winning flower, vape and concentrate brand, Nature’s Heritage™, today announced the launch of ‘The Nose Knows,’ an immersive, science-backed consumer education campaign designed to help consumers better understand which cannabis products and strains align best to their preferences. The campaign aims to educate consumers about the critical role aroma plays in delivering desired cannabis experiences and organizes cannabis strains into six categorizes to make purchase decisions easier and more effective.

Developed in collaboration with Dr. Riley Kirk, a PhD-trained pharmaceutical scientist specializing in cannabis and pharmacology, ‘The Nose Knows’ campaign was inspired by feedback from cannabis consumers surveyed across Massachusetts, Maryland, and Illinois. The survey found that a product’s THC potency percentage is the primary factor influencing purchases. According to Dr. Kirk, research indicates that consumers would achieve a more desirable and personalized experience by focusing instead on their natural attraction to certain scents when making their flower purchase.

“Our sense of smell is intimately tied to our brain’s processing centers for emotions and memory,” said Dr. Kirk. “We want to encourage people to follow their nose to find cannabis that fits their needs and allows for a more personalized and nuanced experience. Terpene labels are a great resource, but they can be confusing to consumers. Following your nose is simple and intuitive for everyone.”

‘The Nose Knows’ campaign features immersive in-store activations, sensory-driven displays, and large-scale murals highlighting six aroma-and-effect-driven categories: Jacks & Haze, Tropical & Citrus, Floral & Earthy, Desserts & Sweets, OG, Gas & Chem, and Exotics. Utilizing local artists to visually depict each intended experience, the campaign transforms participating retail spaces into educational environments that encourage consumers to smell flower and concentrates and use their nose to help discover products that are right for them. Consumers can also explore the campaign through Nature’s Heritage’s online “Find Your Flower” quiz. The quiz helps guide consumers toward products aligned with their preferences and desired effects.

“Today’s cannabis consumer overwhelmingly purchases products based on THC percentage. Cannabis is meant to be experienced through one’s senses, and the science supports the fact that focusing on aroma rather than potency will enhance a consumer’s cannabis experience,” said Tami Kirlis, Brand Director for Nature’s Heritage. “We developed ‘The Nose Knows’ campaign to educate consumers and shift their purchasing behaviors using their sense of smell.”

To learn more about Nature Heritage, including options for flower, RSO, concentrates and vapes, visit www.naturesheritagecannabis.com.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, InHouse™, Nature’s Heritage™, and Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Media Contact:
Zach Galasso
DPA Communications 
Email: [email protected]
Phone: (978) 604-5423

Company Contact:
Howard Schacter
Chief Communications Officer 
Email: [email protected]
Phone: (781) 277-0007

Release – ISG to Announce Second-Quarter Financial Results

Posted on by [email protected]

Research News and Market Data on III

7/7/2026

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, said today it will release its second-quarter financial results on Wednesday, August 5, 2026, at approximately 4:15 p.m., U.S. Eastern Time.

The firm will host a conference call with investors and industry analysts at 9 a.m., U.S. Eastern Time, the following day, Thursday, August 6. Dial-in details are as follows:

  • The dial-in number for U.S. participants is +1 (800) 715-9871.
  • International participants should call +1 (646) 307-1963.
  • The security code to access the call is 2802159.

Participants are requested to dial in at least five minutes before the scheduled start time.

A recording of the conference call will be accessible on ISG’s investor relations page for approximately four weeks following the call.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.

Release – CoreCivic Announces 2026 Second Quarter Earnings Release and Conference Call Dates

Posted on by [email protected]
CoreCivic

Research News and Market Data on CXW

July 7, 2026

PDF Version

BRENTWOOD, Tenn., July 07, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it will release its 2026 second quarter financial results after the market closes on Wednesday, August 5, 2026. A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, August 6, 2026.

To participate via telephone and join the call live, please register in advance. Upon registration at https://register-conf.media-server.com/register/BI99959d3b30da46f3a101e52cd0e2654d, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.

Participants may access the audio-only webcast of the conference call from the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. A replay of the webcast will be available for seven days.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact:Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
 Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Kelly Appoints Alan Stukalsky as Chief Product and Technology Officer

Posted on by [email protected]
Primary Logo

Research News and Market Data on Kelya

July 6, 2026

PDF Version

Industry veteran brings more than 25 years of technology and digital leadership to newly created role

TROY, Mich., July 06, 2026 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a global workforce strategy and solutions provider, has appointed Alan Stukalsky as chief product and technology officer, effective July 13. Stukalsky joins the Kelly senior leadership team, reporting to CEO Chris Layden, and will be responsible for overseeing the company’s product strategy, technology capabilities, and digital innovation efforts across its portfolio of specialty businesses.

“The workforce solutions industry is at an inflection point. Companies who successfully embed AI into their operations to better serve clients and candidates are going to pull away from the field,” Layden said. “That work is already underway at Kelly. Alan will scale it, drive operational excellence across the enterprise, and accelerate the pace at which we’re launching products that will help clients build tech-enabled workforces. He’s done it before and we’re excited to see the impact he’ll bring.”

Stukalsky brings more than 25 years of technology leadership and digital transformation experience to the newly created role. Throughout his career, he has led large-scale modernization efforts, enterprise platform transformations, cloud migrations, AI-enabled innovation, and the development of new digital business models. He is widely recognized for aligning technology, product, and business strategy to create industry-leading talent solutions and deliver measurable outcomes for customers, employees, and shareholders.

Most recently, Stukalsky served as chief digital and information officer at LHH, part of the Adecco Group. Prior to LHH, Stukalsky spent more than 16 years at Randstad, holding dual executive roles as chief digital officer and chief information officer for North America.

“This is an exciting time to join Kelly. The company is investing in the technology and products that will define how it competes in an AI-driven market,” Stukalsky said. “I’m passionate about making it easier for clients and candidates to work with us, embedding AI into the fabric of how we operate, and ensuring the people we place are equipped with the tools they need to succeed. I look forward to partnering with the talented Kelly team to build on a strong foundation and accelerate growth.”

Stukalsky is a passionate advocate for inspiring future STEM professionals and active with Junior Achievement, Georgia State University’s CIS program, and STE(A)M Truck. He has served on numerous industry and community boards and has been recognized as Georgia CIO of the Year for Large Enterprises. He holds a Bachelor of Science in Mechanical Engineering from Georgia Tech and a Bachelor of Science in Mathematics from Emory University.

About Kelly®
Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect approximately 375,000 people with work every year. Our suite of outsourcing and consulting services and solutions ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2025 was $4.3 billion.

Media Contact
Christian Taske
248-561-8823
[email protected]

This press release was published by a CLEAR® Verified individual.

Primary Logo

Release – Xcel Brands Announces Licensing Agreement with KBL Group for OFF/DUTY by Coco Rocha

Posted on by [email protected]
Primary Logo

Research News and Market Data on XELB

PDF Version

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a leading media and consumer products company specializing in influencer-led brands through social commerce and livestream shopping, today announced a licensing agreement with KBL Group for OFF/DUTY by Coco Rocha, the elevated fashion and accessories brand created in collaboration with internationally recognized supermodel, entrepreneur, educator, and fashion icon Coco Rocha.

Under the agreement, KBL Group will serve as the production partner for OFF/DUTY by Coco Rocha’s ready to wear collections, leveraging their expertise in sourcing, product development, manufacturing, and supply chain management to bring the brand’s vision to life. The partnership will support the continued growth of OFF/DUTY by Coco Rocha as the brand expands its fashion offerings across multiple retail distribution channels.

OFF/DUTY by Coco Rocha was created to reflect the realities of modern life, offering elevated wardrobe essentials designed for women constantly on the move. Inspired by the pieces Coco has relied on throughout her two-decade career of fashion weeks, international travel, business meetings, and family life. The brand delivers stylish, versatile, and functional pieces that seamlessly transition from day to night.

“KBL Group brings exceptional expertise in product development and manufacturing, making them an ideal partner for OFF/DUTY by Coco Rocha,” said Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel Brands. “As we continue to build the brand, having a best-in-class partner capable of executing Coco’s vision with the highest standards of quality and craftsmanship is critical. We are excited to work together to create collections that resonate with today’s modern consumer.”

David Guisinger, Chief Executive Officer of KBL Group, added, “We are proud to partner with XCEL Brands and OFF/DUTY by Coco Rocha to bring a modern approach to dressing that is both aspirational and accessible. Coco’s authentic point of view and deep understanding of how women dress today have created a powerful foundation for the brand. By combining XCEL’s innovative approach to brand building with KBL’s expertise in product development, sourcing and execution, we are creating a meaningful lifestyle brand that reflects today’s consumer, confident, versatile and effortlessly sophisticated, while developing growth opportunities across multiple channels of distribution.”

About Xcel Brands

Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods, pet products and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel is an industry leader in developing influencer led brands and owns the Halston and C. Wonder brands, as well as the co-branded influencer led brands Tower Hill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford and OFF/DUTY by Coco Rocha brand and holds a long-term license agreement in Mesa Mia by Jenny Martinez. Xcel also owns and manages the Longaberger by Shannon Doherty brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers’ shop. The company’s previously owned and current brands have generated more than $5 billion in retail sales via livestreaming in interactive television and digital channels alone and has over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches more than 46 million social media followers with broadcast reaching 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.

For further information please contact:

Xcel Brands
[email protected]

About KBL Group

KBL Group is a globally-focused fashion brand development and sourcing partner that supports retailers and designers at every stage of the product lifecycle.  With a legacy that traces back to 1985, KBL has evolved into a strategic extension of its clients’ teams, blending market insight, creative design and international supply chain execution into comprehensive brand solutions.  Today, KBL Group operates with an integrated presence in New York and Hong Kong, aligning it’s global expertise to help fashion and lifestyle brands navigate a competitive, rapidly-changing marketplace.

For further information please contact:

KBL Group
[email protected]

About Coco Rocha

Coco Rocha is an internationally recognized supermodel, entrepreneur, educator, author, mentor, and advocate. Often referred to as the “Queen of Pose,” she has spent more than two decades at the forefront of the fashion industry, appearing on hundreds of magazine covers, walking for the world’s leading luxury brands, and starring in major global advertising campaigns.

Beyond modeling, Rocha has built a successful business career spanning fashion, education, television, and digital media. She is the founder of Coco Rocha Model Camp, where she has mentored thousands of aspiring and professional models from around the world, and currently serves as mentor and host of Project Runway Canada. Known for combining creativity, entrepreneurship, and education, Rocha continues to shape the future of fashion while inspiring audiences through her work as a businesswoman, mentor, and mother.

Primary Logo

Release – NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: “A Quest to Outrun ALS”

Posted on by [email protected]

Research News and Market Data on NRSN

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC’s path forward

CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled “A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS).” The webinar will bring together leading experts to discuss the current treatment landscape for ALS, persistent unmet medical needs, and emerging therapeutic approaches with the potential to change the course of the disease.

The live webinar will take place on Wednesday, July 8, 2026, at 11:00 a.m. Eastern Time and will be hosted by Boobalan Pachaiyappan, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, who covers the biotechnology sector. The discussion will feature Professor Jeremy Shefner, M.D., Ph.D., Chair of Neurology at Barrow Neurological Institute and Co-Founder of the Northeast ALS Consortium (NEALS), together with Alon Ben-Noon, Chief Executive Officer of NeuroSense.

To join the conversation, register in advance here.

The webinar will explore the most pressing questions in ALS drug development today – from the persistent unmet needs that continue to challenge patients and clinicians, to the clinical trial endpoints that may better capture disease progression. The discussion will also examine how NeuroSense’s PrimeC is positioned – mechanistically and clinically – relative to the current standard of care, what the pivotal Phase 3 PARAGON study will aim to demonstrate on the path toward potential FDA accelerated approval, and PrimeC’s longer-term commercial opportunity within an evolving ALS treatment landscape.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC’s multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the planned event, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: Email: [email protected] | Tel: +972 (0)9 799 6183

Release – Kratos Expands Oklahoma City Manufacturing Facility to Accelerate Production of Valkyrie, Firejet and Other Jet Drone Systems

Posted on by [email protected]
Primary Logo

Research News and Market Data on KTOS

July 6, 2026

PDF Version

106,000 Square Foot Facility Expansion Reflects Increased Demand for Kratos Jet Drones and Kratos’ Continued Investment in Strengthening the United States Defense Industrial Base Through Scalable, Efficient Manufacturing Capacity Capable of Producing Affordable, Mission-Ready Systems at Quantity and at Speed

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, today announced a major expansion of its Oklahoma City manufacturing campus with the addition of over 100,000 square feet of manufacturing and production space. The expansion supports increasing customer demand for the company’s family of high-performance, affordable jet-powered drone systems, including the Valkyrie collaborative combat aircraft, the Firejet/Mighty Hornet IV and others.

The facility expansion represents Kratos’ continued investment in strengthening the United States defense industrial base through scalable, efficient manufacturing capacity capable of producing affordable, mission-ready systems at quantity and at speed. Today, Kratos produces approximately 165 high-performance jet drones annually, and this expansion will enable the company to further increase production to meet growing demand from the U.S. Department of War and allied customers.

“The future fight demands the ability to rapidly produce affordable, high-performance systems at scale,” said Steve Fendley, President of Kratos Unmanned Systems Division. “This expansion in Oklahoma City reflects our long-term commitment to investing ahead of customer demand and building the industrial capacity needed to support the Department of War’s modernization priorities. As autonomous systems become increasingly central to the future force, manufacturing readiness and producing at scale will be just as important as technology readiness, maybe more.”

The expanded facility will provide additional manufacturing, assembly, integration and test capacity for multiple Kratos tactical jet aircraft programs.

Production will support Valkyrie, the affordable, runway-flexible collaborative combat aircraft selected by the U.S. Marine Corps as the foundation of its Collaborative Combat Aircraft (CCA) program of record. Designed to operate solo, in swarms, or alongside crewed aircraft while providing additional mass, reach and mission capability, Valkyrie represents a new generation of affordable autonomous airpower. The expanded facility will also manufacture the Mighty Hornet IV, which is expected to serve as a key tactical capability supporting Taiwan’s defense requirements, reflecting growing international demand for affordable, high-performance unmanned systems.

The expanded facility will also support increased production capacity for Kratos’ family of high-performance aerial target systems, including the Firejet. Kratos’ Firejet system supports realistic operational test, evaluation and weapons training across the U.S. military and allied nations, with demand for advanced target capabilities continuing to grow, including for the test and training of missile, radar, air defense, C-UAS and directed energy weapon systems, and their crews.

Kratos has consistently invested in manufacturing infrastructure, production technologies, and workforce development to ensure the company can deliver affordable systems at the pace and scale required by evolving national security needs. The Oklahoma City expansion is the latest in a series of investments focused on expanding domestic production capacity and strengthening the resilience of the U.S. defense industrial base.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

Primary Logo

Release – CoreCivic Sells Two Detention Facilities\

Posted on by [email protected]
CoreCivic

Research News and Market Data on CXW

July 6, 2026

PDF Version

BRENTWOOD, Tenn., July 06, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (CoreCivic or the Company) announced today that on July 2nd, 2026, it completed the sale of its 2,560-bed California City Detention Facility in California City, California (the California City Facility) and its 1,994-bed Otay Mesa Detention Center in San Diego, California (the Otay Mesa Facility) to the United States of America and its assigns, by and through the Department of Homeland Security for an aggregate gross sales price of $1.5 billion, including $732.6 million for the California City Facility and $739.2 million for the Otay Mesa Facility. These two purpose-built facilities were specifically designed to care for individuals in a secure environment. After federal and state income taxes of approximately $0.4 billion and transaction expenses, the Company anticipates its net proceeds from the asset sales to be approximately $1.1 billion.

The Company expects to use a portion of the net proceeds from the asset sales to

  • Repay all or a portion of the outstanding indebtedness under the Company’s Bank Credit Facility, which currently has an outstanding balance of $270.0 million on the Revolving Credit Facility, $107.8 million on the Initial Term Loan, and $100.0 million on the Incremental Term Loan, and
  • Repay the remaining outstanding balance of $238.5 million of the Company’s 4.75% senior notes, which are scheduled to mature in October 2027 (the 4.75% Notes).

The Company expects to use the remaining net proceeds for general corporate purposes, which may include additional debt repayments and share repurchases of the Company’s common stock. The credit agreement governing the Company’s Bank Credit Facility (the Credit Agreement) and the indenture (the 2029 Notes Indenture) governing the Company’s outstanding 8.25% senior notes due 2029 (the 8.25% Notes) limit our ability to make certain restricted payments, including share repurchases. However, the Company is permitted to make unlimited restricted payments (i) under the Credit Agreement, to the extent the Company’s consolidated secured leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 1.50 to 1.00 and no default exists thereunder, and (ii) under the 2029 Notes Indenture, to the extent the Company’s consolidated total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.00 to 1.00. 

The Company also expects to maintain balance sheet flexibility to pursue growth opportunities. These opportunities include, but are not limited to, potential acquisitions within the Company’s lines of business and those that provide complementary services provided such opportunities enhance the Company’s business, diversify the Company’s cash flows, and/or increase the services the Company offers to its customers, similar to the acquisition of Clinical Solutions Pharmacy completed on April 1, 2026.

The Company currently expects to continue to manage the California City Facility and the Otay Mesa Facility under the existing management contracts with Immigration & Customs Enforcement (ICE) related to each facility, although the terms of the management contracts may be modified to reflect the change in ownership. However, the Company can provide no assurance that it will continue to manage these facilities in the future, or that the terms of the existing management agreements will remain the same. As has always been the case, ICE has the ability to terminate the management contracts for non-appropriation of funds or for convenience. The management contract for the California City Facility expires in August 2027, and the management contract for the Otay Mesa Facility expires in December 2029 and contains a five-year extension option.

In addition to these asset sales, the Company has been in discussions with ICE about the potential acquisition of additional detention facilities from the Company. These discussions are in various stages, and the Company can provide no assurance that any additional sales will occur.

Patrick Swindle, CoreCivic’s President and Chief Executive Officer, commented, “We are pleased with the sales of these two mission-critical facilities for the Company’s government partner, which demonstrates the value of the Company’s underlying real estate portfolio, while reflecting our role as a long-term, flexible solutions provider to government. The sale of these facilities at what we believe is a fair valuation provides the Company with significant balance sheet flexibility and positions us well to grow the Company’s businesses and return value to its shareholders, while remaining a dependable partner for government.”

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. CoreCivic has been a flexible and dependable partner for government for more than 40 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Forward-Looking Statements

This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These include, but are not limited to, the risks and uncertainties associated with: (i) changes in government policy, legislation and regulations that affect utilization of the private sector for corrections, detention, and residential reentry services, in general, or our business, in particular, including, but not limited to, the continued utilization of our correctional and detention facilities by the federal government as a consequence of presidential executive orders, changes in how the federal government, including ICE, elects to use our detention capacity or otherwise procures alternative detention capacity, and the impact of any changes to immigration reform and sentencing laws (we do not, under longstanding policy, lobby for or against policies or legislation that would determine the basis for, or duration of, an individual’s incarceration or detention); (ii) our ability to obtain and maintain correctional, detention, and residential reentry facility management contracts because of reasons including, but not limited to, sufficient governmental appropriations, contract compliance, negative publicity and effects of inmate disturbances; (iii) changes in the privatization of the corrections and detention industry, the acceptance of our services, the timing of the opening of new facilities and the commencement of new management contracts (including the extent and pace at which new contracts are utilized), as well as our ability to utilize available beds; (iv) our ability to successfully activate idle facilities in a timely manner in order to meet the growth in demand for our facilities and services from the federal government that has occurred as a result of changes in policies and actions of the current presidential administration, and to realize projected returns resulting therefrom; (v) general economic and market conditions, including, but not limited to, the impact governmental budgets can have on our contract renewals and renegotiations, per diem rates, and occupancy; (vi) fluctuations in our operating results because of, among other things, changes in occupancy levels; competition; contract renegotiations or terminations; inflation and other increases in costs of operations, including a rise in labor costs; fluctuations in interest rates and risks of operations; (vii) government budget uncertainty, the impact of debt ceilings and government shutdowns, including partial shutdowns, and changing budget priorities; (viii) our ability to successfully identify and consummate future development and acquisition opportunities, integrate their operations, and realize projected returns resulting therefrom; (ix) the availability of debt and equity financing on terms that are favorable to us, or at all; and (x) the potential for additional sales and intended use of proceeds from the asset sales described in this press release. Other factors that could cause operating and financial results to differ are described in the filings we make from time to time with the Securities and Exchange Commission.

We take no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services, except as may be required by law.

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, including the 4.75% Notes or the 8.25% Notes, nor shall it constitute a notice of redemption under the indenture governing the 4.75% Notes or the 2029 Notes Indenture, nor shall there be any offer, solicitation or sale of the 4.75% Notes, the 8.25% Notes or any other securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

Contact: Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
Financial Media: David Gutierrez, Dresner Corporate Services – (312) 780-7204

Release – FreightCar America, Inc. Announces Milestone Multi-Year Order for 1,900 Railcars; Second Quarter Orders for Approximately 3,000 Railcars Represent a Commercial Inflection Point

Posted on by [email protected]
FreightCar America

Research News and Market Data on RAIL

07/06/2026

New Multi-Year Railcar Order Extends Backlog Visibility and Supports Second Quarter Commercial Momentum, Reflecting Customer Confidence in FreightCar America’s Commercial, Engineering and Manufacturing Platform

CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a leading North American manufacturer and supplier of freight railcars, railcar parts and components, today announced that it has entered into a new multi-year order for 1,900 railcars from a key customer, with deliveries scheduled through 2028. The Company also announced that second quarter orders totaled approximately 3,000 railcars, representing a commercial inflection point as demand for differentiated, agile manufacturing solutions continues to grow.

Highlights

  • Secured a new multi-year order for 1,900 railcars, with deliveries scheduled through 2028, expanding backlog visibility and reflecting customer confidence in the Company’s execution and manufacturing capabilities.
  • Second quarter orders totaled approximately 3,000 railcars, valued at approximately $300 million, with orders received across every core market segment, reflecting broad-based demand and product diversity.
  • Multiple first-time customer orders, together with meaningful repeat customer activity, underscore strength of commercial presence, product offering and manufacturing platform.

“Customers are increasingly choosing FreightCar America because we are delivering what the market needs in conditions where customers need us most. Anchored by our engineering capability, manufacturing agility and focus on quality, we continue to position ourselves to gain share and capture significant order momentum during the quarter,” commented Nick Randall, President and Chief Executive Officer of FreightCar America. “This new multi-year commitment for 1,900 railcars is a testament to that, marking a milestone for the Company and showcasing the confidence our customers put into our ability to execute over a sustained delivery horizon.”

Randall continued, “With approximately 3,000 railcars ordered in the quarter, we are seeing an inflection point in terms of commercial momentum across our differentiated product portfolio. These orders highlight the value customers place on our ability to move quickly, tailor solutions to their needs and support transportation capacity across the North American supply chain. We believe FreightCar America is well positioned as an execution-focused railcar manufacturer in a market where reliability, responsiveness and delivery performance matter more than ever.”

Certain orders referenced in this release are subject to customary documentation and completion of terms.

About FreightCar America

FreightCar America, headquartered in Chicago, Illinois, is a leading designer, producer and supplier of railroad freight cars, railcar parts and components. We also specialize in railcar repairs, complete railcar rebody services and railcar conversions that repurpose idled rail assets back into revenue service. Since 1901, our customers have trusted us to build quality railcars that are critical to economic growth and instrumental to the North American supply chain. To learn more about FreightCar America, visit www.freightcaramerica.com.

Forward-Looking Statements

This press release contains statements relating to our expected financial performance, financial condition, and/or future business prospects, events and/or plans that are “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates and assumptions only as of the date of this press release. Our actual results may differ materially from the results described in or anticipated by our forward-looking statements due to certain risks and uncertainties. These potential risks and uncertainties relate to, among other things, the cyclical nature of our business; adverse economic and market conditions, including inflation; material disruption in the movement of rail traffic for deliveries; fluctuating costs of raw materials, including steel and aluminum; delays in the delivery of raw materials; our ability to maintain relationships with our suppliers of railcar components; our reliance upon a small number of customers that represent a large percentage of our sales; the variable purchase patterns of our customers and the timing of completion, delivery and customer acceptance of orders; the highly competitive nature of our industry; potential unexpected changes in laws, rules, and regulatory requirements, including tariffs and trade barriers; and other competitive factors. We expressly disclaim any duty to provide updates to any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise.

Investor Contact: [email protected]

Primary Logo

Source: FreightCar America, Inc.

View all news

Release – NN, Inc. Announces Major Breakthrough in its Medical Business

Posted on by [email protected]
Primary Logo

Research News and Market Data on NNBR

PDF Version

NN to manufacture critical components for a leading robotic-assisted surgery platform


CHARLOTTE, N.C., July 06, 2026 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR) (“NN” or the “Company”), a global diversified industrial company that engineers, co-develops and manufactures precision components and assemblies with six sigma quality, today provided an update on developments in its Medical Products business, one of the Company’s key targeted growth markets. The components of the Medical Products growth program are:

  • Specialized quality control systems in the plants that make medical products
  • Dedicated, specialized CNC machining equipment
  • Dedicated special purpose floor space
  • Medical industry experts on staff
  • Attendance at top medical device shows
  • State-of-the-art stainless steel machined products
  • Global footprint in North America, China, South America, Europe

NN has achieved awards to support major OEMs in Ultrasound, Interventional Cardiology, Sports Medicine & Extremity Solutions, and Robotic-Assisted Surgery. Robotic-Assisted Surgery is a new breakthrough area of success and the focus of this press release. NN has now become qualified and has received initial POs tied to a leading robotic-assisted surgery platform. This momentum complements NN’s legacy medical work in surgical instruments, orthopedic tools/components, electrosurgical products, suture-related products, and precision medical components.

A recent and most difficult step to entering the Robot-Assisted Surgery market was passing a critical full-facility audit at NN’s Kentwood, Michigan plant. Successfully passing this audit was made possible by completing a multi-year investment program and installing a new quality system. With this new medical certification now steady-state, a large and well-known new customer has released its first purchase orders to NN, with immediate delivery and ramp-up requirements. This also provides NN with references and an avenue to quote and win additional programs.

With this new customer, the new medical certification, and new medical products, NN’s medical new business pipeline has increased in size by ~$25 million and is now approximately $75 million overall. This is now a meaningful component of NN’s total corporate new business pipeline of >$750 million which includes all products for all markets.

Robotic-assisted surgery is the fastest-growing method of surgical care, expanding at double-digit annual rates in the United States. The underlying growth of this key market reflects a strong secular growth opportunity for precision component suppliers like NN that possess the critical engineering capability, quality systems, and global manufacturing footprint to serve it. NN is uniquely positioned to participate in medical market growth as a qualified manufacturer. NN is actively investing into the medical market with dedicated staff, tradeshow attendance, additional equipment, and new products.

Harold Bevis, President and Chief Executive Officer of NN, Inc., commented, “This is a milestone event for NN’s medical products growth program and a direct payoff on the investments we have made over the last three years to establish a premier presence in this medical market. We needed to upgrade our quality system to the medical level and we have done it.

“Medical Products is one of our five targeted growth markets and we have been very deliberate about building the capabilities required to compete and win. This includes specialized machines, dedicated floor space, certified quality systems, and a dedicated medical team. Passing this full facility quality audit and securing our first newly associated purchase orders to make precision components for a leading robotic surgery platform is a good step forward for NN.”

Bevis continued, “Our precision stainless steel machining expertise supports these new markets well. We are successfully executing on our stated growth goals in the medical products market, and we intend to both grow with this particular customer, as well as more fully participate in the broader medical market.

“This medical products achievement is consistent with our growth program overall. We are partnering for long-term success with OEM category winners. We are successfully building the Company’s business profile in new markets and with new customers. Safety-critical, engineered components are our core value proposition. We support it with a clever team, material science, six sigma quality, and global manufacturing footprint. The medical products achievements announced today, combined with the strong momentum we are experiencing in data center and defense, continue to demonstrate that our entrepreneurial breakout growth program is working well.”

Bevis concluded, “NN is underway with a multi-year program of growing its business into new areas. It is awesome to have the Medical Products portion of the 5 Pillar growth program achieving breakthrough victories. The 5 pillars of break-out growth continue to be: data center and electric grid, defense and electronics, medical products, high-value vehicle products, and high-value stamped products.

We will combine this Medical Product new win information with our recent new wins in Data Center and adjust 2026 sales, adjusted EBITDA, and New Wins guidance, if needed, during NN’s next business and guidance update in August. We look forward to discussing this big advancement during that time.”

About NN, Inc.
NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, South America, Europe, and China. For more information about the company and its products, please visit www.nninc.com.

Forward-Looking Statements
This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the future growth of NN’s medical business, including NN’s expectations regarding current and future customers and programs, the size and future outlook of the medical market, including robotics-assisted surgery, NN’s competitive position in the medical market, expected new business wins for 2026, and NN’s 2026 performance and other statements that are not historical facts.

Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project”, “achieve,” “growth,” “enable,” “improve,” or the negative of these terms, and similar words, phrases or expressions that convey uncertainty of future events or outcomes. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such statements. Such factors include, among others, general economic conditions and economic conditions in the industrial sector; competitive influences; risks that current customers will commence or increase captive production; risks of capacity underutilization; quality issues; inflationary pressures and material changes in the costs and availability of raw materials, supply chain shortages and disruptions, the availability of labor and labor distributions along the supply chain; our dependence on certain major customers, some of whom are not parties to long-term agreements (and/or are terminable on short notice); the impact of acquisitions and divestitures, as well as expansion of end markets and product offerings; our ability to hire or retain key personnel; the restrictions contained in our debt agreements; the level of our indebtedness and our ability to financing at favorable rates, if at all, or to refinance existing debt as it matures; our ability to secure, maintain or enforce patents or other appropriate protections for our intellectual property; the impact on climate change on our operations; economic, social and geopolitical instability, military conflict, currency fluctuations, and other risks of doing business outside of the United States; and uncertainty of government policies and actions in respect to global trade and tariffs, including the potential impacts of tariffs on the United States economy, the economy of other countries in which we conduct operations and our industry, cyber liability or potential liability for breaches of our or our service providers’ information technology systems or business operations disruptions. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the U.S. Securities and Exchange Commission. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.

Investor & Media Contact: 
Joe Caminiti  
[email protected]
312-445-2870

Robotic Surgery Machine
 

NN Medical Surgery Image
Robotic Surgery Machine

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1db7369d-ec70-40e1-81f7-bf89fbbb3544

Primary Logo

Release – DLH Announces Leadership Transition

Posted on by [email protected]
logo

Research News and Market Data on DLHC

June 30, 2026

PDF Version

Zach Parker to Retire; Kathryn JohnBull Appointed CEO; Steve Oroho Appointed CFO

ATLANTA, June 30, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science research and development solutions to federal agencies, today announced the following leadership changes:

  • Zach Parker will retire from the role of Chief Executive Officer
  • The Board has appointed Kathryn JohnBull as CEO
  • The Board has appointed Steve Oroho as Chief Financial Officer

Zach Parker

Zach Parker will retire as DLH’s Chief Executive Officer and President effective at the close of business on June 30, 2026. To support a smooth leadership transition, Mr. Parker will remain with the Company as an advisor to the Board and incoming CEO through the end of the current fiscal year. He will continue to serve as a member of the Board and beginning in fiscal 2027 will serve as a consultant to the Company in support of certain strategic growth pursuits.

“Sixteen years ago, Zach Parker became the CEO of a $35 million revenue company that was insignificant to the Government Services industry,” said Chairman of the Board Rick Wasserman. “He built a team, and together, they built that organization into the DLH of today. His accomplishments have been exemplary in shaping the Company’s success and creating significant value for our shareholders and career opportunities for our employees. We are grateful for his leadership and pleased that the Company will continue to benefit from his deep industry knowledge, strategic perspective, and longstanding relationships through his continued service on the Board. We are also appreciative that the team he built is uniquely qualified and well positioned to lead us into the future. We wish Zach a long and enjoyable retirement and much happiness in the future.”

“I am proud of what our team has accomplished and excited about DLH’s future,” said Mr. Parker. “After 16 years as CEO, I believe this planned transition represents the right next step for the Company and for me personally. Kathryn has been a close partner, and I have great confidence in her ability to lead the Company through its next chapter. I look forward to supporting Kathryn, the leadership team, and the Board as we continue working to create sustainable long-term value for our shareholders.”

Kathryn JohnBull

Kathryn JohnBull has been appointed as DLH’s Chief Executive Officer and President upon Mr. Parker’s retirement. Ms. JohnBull brings deep public-company leadership experience, financial discipline, and a thorough understanding of the government services market to her new role. She joined DLH as Chief Financial Officer in 2012, and has been central to the Company’s growth, acquisition strategy, capital markets activities, financial operations, and investor engagement.

“Kathryn is exceptionally well prepared to lead DLH at this important moment in the Company’s evolution,” Mr. Wasserman continued. “During her 14 years with us, she has demonstrated a strong combination of leadership skills, financial acumen, operating discipline, customer understanding, and public-company experience. This promotion is well earned, and the Board is confident that Kathryn and her leadership team are well positioned to advance the Company’s strategy and compete for new business opportunities, which create value for our shareholders.”

“I am honored to lead DLH as we enter the next stage of our corporate journey,” said Ms. JohnBull. “Our company has been built by talented people, highly valued customer relationships, and an unwavering commitment to supporting critical government missions. As we look ahead, our focus will be clear: executing with discipline and excellence, delivering exceptional value for our customers, and investing in and empowering our employees. By embracing innovation and strengthening the capabilities that differentiate DLH, we will continue building a company where our employees will grow, our customers will be well served, and our business will thrive.”

Steve Oroho

Steve Oroho has been appointed as DLH’s Chief Financial Officer and Treasurer upon Ms. JohnBull’s appointment as CEO. Mr. Oroho joined DLH in 2018 and has served as Senior Vice President, Finance & Accounting. In that role, he has played an important part in the Company’s financial reporting, strategic planning, accounting, treasury, and business operations support. As Chief Financial Officer, Mr. Oroho will lead DLH’s finance organization, including accounting, financial planning and analysis, treasury, tax, investor relations, and related financial operations.

“Steve has been an important member of DLH’s finance leadership team and brings deep knowledge of the Company’s operations, financial systems, and strategic priorities,” said Ms. JohnBull. “His experience, judgment, and commitment to disciplined execution will serve DLH well as we continue to advance our strategic and financial objectives.”

“I am grateful for the opportunity to serve as DLH’s Chief Financial Officer,” said Mr. Oroho. “I look forward to continuing to work closely with Kathryn, the Board, and our leadership team to support our customers, strengthen our operating performance, and create sustainable value for our shareholders.”

About DLH:

DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com. 

Contact Information:

Investor Relations
Chris Witty
(646) 438-9385
[email protected]

Media
[email protected]

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding the anticipated use of proceeds. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities; legal, regulatory, and political changes from the federal government that could result in economic uncertainty; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather based on current expectations, estimates, assumptions and projections about our industry and business.

Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.